Peripheral blood stem cell transplantation

Vox Sanguinis

Volumn 73, Issue 3, 1997, Pages 135-142

  Watts, M J ^a   Lincli, D C ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR;

APHERESIS; CANCER THERAPY; COLONY FORMING CELL; GRANULOCYTE; HUMAN; HUMAN CELL; MONOCYTE; PERIPHERAL BLOOD STEM CELL; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION;

BLOOD SPECIMEN COLLECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MONITORING, PHYSIOLOGIC; NEOPLASMS; PHLEBOTOMY; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030681330     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.1997.7330135.x     Document Type: Article

References (89)

1. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV: Dose intensification with autologous bone marrow transplantation is effective in relapsed and resistant Hodgkin's disease: Results of a BNLI randomized trial. Lancet 1993; 341:138-142.
2. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. N EngUMed 1995;333:1540-1545.
3. Haioun C, Lepage E, Gisselbrecht Ch, Coffier B, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Briere J, Gaulard Ph, Reyes F: Autologous bone marrow transplantation (ABMT) versus sequential chemotherapy for aggressive non-Hodgkin's lymphoma (NHL) in first remission (CR): A study of 542 patients (LNH87-2 protocol) (abstract 1816). Blood 1995;86:457a.
4. Bezwoda WR, Seymour L, Dansey RD: High dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomised trial. J Clin Oncol 1995;13: 2483-2489.
5. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibct JG, Rossi JF, Casassus P, Maisonneuve H, Façon T, Ifrah N, Payen C, Bataille R: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N End J Med I996;335:9197.
6. Gianni AM, Bregini M, Siena S, Villa S, Sciorelli GA, Ravagnani F, Pellegris G, Bonadonna G: Rapid and complete haemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo/radiolherapy? Hematol Oncol 1989;7:139-148.
7. Beyer J, Schwella N, Zingsem J, Strohscheer I, Schwaner I, Oettle H, Serke S, Huhn D, Stieger W: Hematopoietic rescue after high dose chemotherapy using autologous peripheral blood progenitor cells or bone marrow: A randomized comparison. J Clin Oncol 1995; 13:1328-1335.
8. Schmilz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HM, Link H, Zander A, Barge A, Borkett K: Randomised trial of filgrastim mobilised peripheral blood progenitor cell transplant versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996;347:353-357.
9. Smith TJ, Hillner BE, Schmilz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Link H, Zander A, Yancovich S, Kitchin R, Erder MH: Economic analysis of a randomized clinical trial lo compare filgraslim mobilized peripheral blood transplantalion and aulologous bone marrow transplanlation in patienls wilh Hodgkin and non-Hodgkin lymphoma. J Clin Oncol 1997;15:5-10.
10. Jones HM, Jones SA, Watts MJ, Khwaja A, Mills W, Fielding A, Goldstone AH, Linch DC: Development of a simplified apheresis approach for PBSC transplantation in previously treated patients with lymphoma. J Clin Oncol 1994; 12:1693-1702.
11. Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Sweet D: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993;82:2605-2610.
12. Brecher G, Cronkite EP: Postirradiation parabiosis and survival in rats. Proc Soc Exp Biol Medl951;77:292-294.
13. Goodman JW, Hodgson GS: Evidence of stem cells in the peripheral blood of mice. Blood 1962;19:702-714.
14. Hershko C, Gale RP, Ho WG, Cline MJ: Cure of aplastic anaemia in paroxysmal nocturnal hacmoglobinuria by marrow transfusion from identical twin: Failure of peripheral leukocyte transfusion to correct marrow aplasia. Lancet 1979;i: 945-947.
15. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD: Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988;71:723-727.
16. Lobo F, Kessinger A, Landmark JD, Smith DM, Weisenburger DD, Wigton RS, Armitage JO: Addition of peripheral blood stem cells collected without mobilization techniques to transplanted autologous bone marrow did not hasten marrow recovery following myeloablative therapy. Bone Marrow Transplant 1991 ;8:389-392.
17. Richman CM, Weiner RS, Yankee RA: Increase in circulating stem cells following chemotherapy in man. Blood 1976;47:1031-1039.
18. Juttner CA, To LB, Haylock DN, Branford A, Kimber RJ: Circulating autologous stem cells collected in very early remission from acute ' nonlymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstruction after high dose melphalan or supralethal chemoradiotherapy. Br J Haematol 1985;61:739-745.
19. Reiffers J, Bernard P, David B, Vezon G, Sarrat A, Marit G, Moulinier J, Braustet A: Successful autologous transplantation with peripheral blood haemopoietic cells in patients with acute leukaemia. ExpHematol 1986;14:312-315.
20. Korbling M, Dorken B, Ho AD, Pezzutto A, Hunstein W, Fliedner TM: Autologous transplantation of blood derived haemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986;67:529532.
21. Dursten U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Mecalf D: Effects of G-CSF on haematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-2081.
22. Socinski MA, Elias A, Schnipper L, Cannisatra SA, Antman KH, Griffm JD: GM-CSF expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988;11:1194-1198.
23. Linch DC, Watts MJ: Standards for PBSC mobilisation and collection. Ann Oncol 1996; 7(suppl2):9-10.
24. Sutherland HJ, Lansdorp PM, Henkelman DH, Eaves AC, Eaves CJ: Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc Natl Acad Sci USA 1990;87:3584-3588.
25. Jones RJ, Wagner JE, Celano P, Zicha MS, Sharkis SJ: Separation of pluripotent haematopoietic stem cells from spleen colony forming cells. Nature 1990;347:188-189.
26. Kaiser H, Stuart RK, Brookmeyer R, Beschorner WE, Braine HG, Burns WH, Fuller DJ, Korbling M, Mangan KF, Saral R: Autologous bone marrow transplantation in acute leukaemia: A phase 1 study of in vitro treatment of marrow with 4-hydroperoxy-cyclophosphamide to purge tumour cells. Blood 1985;65:1504-1510.
27. Robertson MJ, Soiffer RJ, Freedman AS, Rabinowe SL, Anderson KC, Ervin TJ, Murray C, Dear K, Griffin JD, Nadler LM: Human bone marrow depleted of CD33 positive cells mediates delayed but durable reconstitution of haemopoiesis: Clinical trial of MY9 monoclonal antibody purged autografts for the treatment of acute myeloid leukaemia. Blood 1992;79: 2229-2236.
28. Siena S, Bregni M, Brando B, Belli N, Ravagnani F, Gandola L, Stern AC, Lansdorp PM, Bonadonna G, Gianni AM: Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1989;74:1905-1914.
29. Sovalat H, Wunder E, Simmerman R: Multicentric determination of CD34+ cells; in Wunder E, Socalat H, Henon P (eds): Hematopoietic Stem Cells: The Mullhouse Manual. Ohio, Dayton Alphamed Press, 1994, pp 61-66.
30. Spitzer G, Verma DS, Fisher R, Zander A, Vellekoop L, Litam J, McCredie K, Dicke K: The myeloid progenitor cell - Its value in predicting haematopoietic recovery after autologous bone marrow transplantation. Blood 1980;55:317323.
31. Gorin NC: Collection, manipulation and freezing of haematopoietic stem cells. Clin Haematol!986;15:19-18.
32. Demirer T, Besinger WI: Optimisation of peripheral blood stem cell collection. Curr Opin Haematol 1995;2:219-226.
33. Watts MJ, Sullivan AM, Jamieson E, Pearce R, Fielding A, Goldstone AH, Linch DC: Progenitor cell mobilisation after low dose cyclophosphamide and G-CSF: An analysis of progenitor cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 15:535-546.
34. Dreger P, Kloss M, Petcrsen B, Haferlach T, Loffler H, Loeffler M, Schmilz N: Autologous progenitor cell transplantation: Prior exposure to stem cell-toxic drugs determines yield and engraftmcnt of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995;86: 3970-3978.
35. Watts MJ, Sullivan AM, Jamieson E, Chavda N, Fielding A, Goldstone AH, Linch DC: A single apheresis algorithm for PBSCT (abstract 79). BrJHacmatoll995;89:22a.
36. Haas R, Wilt B, Mohle R, Goldschmidt H, Hohaus S, Freuhauf S, Wannenmacher M, Hunstein W: Sustained long term hcmatopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood 1995;85:37543761.
37. Schwella N, Siegert W, Beyer J, Rick O, Zingsem J, Eckstein R, Serke S, Huhn D: Autografting with blood progenitor cells: Predictive value of preapheresis blood cell counts on progenitor cell harvest and correlation of the reinfused cell dose with hematopoietic reconstitution. AnnHematol 1995;71:227-234.
38. Elliott C, Samson DM, Armitage S, Lyttelton MP, McGuigan D, Hargreavcs R, Giles C, Abrahamson G, Abboudi Z, Brcnnan M, Kanfer EJ: When to harvest peripheral-blood stem cells after mobilization therapy: Prediction of CD34positive cell yield by preceding day CD34-positive concentration in peripheral blood. J Clin Oncol 1996;14:970-973.
39. Mohle R, Pforsich M, Fruehauf S, Witt B, Krämer B, Haas R: Filgrastim postchemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady state hematopoiesis. Bone Marrow Transplant 1994;14:827-832.
40. Kobayashi N, Kasai M, Masauzi N, Ogasawara M, Kiyama Y, Naohara T, Higa T, Hashino S, Tanaka J: Comparison of peripheral blood stem cells mobilized with granulocyte colony-stimulating factor with or without prior standarddose chemotherapy in patients with malignancy. Jpn J Clin Oncol 1995;25:250-257.
41. Rowlings PA, Bayly JL, Rawling CM, Juttner CA, To LB: A comparison of peripheral blood stem cell mobilization after chemotherapy with cyclophosphamide as a single agent in doses of 4 g/m2 or 7 g/m2 in patients with advanced cancer. Aust NZ J Med 1992;22:660-664.
42. Rosenfeld CS, Shadduck RK, Zeigler ZR, Andrews F, Nemunaitis J: Cyclophosphamide mobilized peripheral blood stem cells in patient with lymphoid malignancies. Bone Marrow Transplant 1995;15:433-438.
43. Valasquez WS, McLaughlin P, Tucker S, Hagemeister FB, Swan F, Rodriguez MA, Ramaguera J, Rubenstein E, Cabanlos F: ESHAP - An effective chemotherapy regimen in refractory and relapsing lymphoma: A four year follow-up study. J Clin Oncol 1994;12:1169-1176.
44. Watts MJ, Leverett D, Sullivan AM, Peniket AJ, Perry AR, MacMillan A, Goldstone AH, Linch DC: A comparison of ESHAP + G-CSF vs cyclophosphamide 1.5 g/m2 + G-CSF for PBSC mobilisation in pretreated lymphoma patients: A matched pair analysis. Blood 1996;88:396a.
45. Peters WP, Rosner G, Ross M, Vredenburgh J, Meisenberg B, Gilbert C, Kurtzberg J: Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after highdose chemotherapy. Blood 1993 ;81:17091719.
46. Demuynck H, Delforge M, Verhoef G, Zachee P, Vandenberghe P, Boogaerts M: Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF. Br J Haematol 1993; 90:384-392.
47. Hoglund M, Smedmyr B, Simonsson B, Tbtterman T, Bengtsson M: Dose dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHu G-CSF: Bone Marrow Transplant I996;18:1927.
48. Roberts AW, DeLuca E, Begley CG, Basser R, Grigg AP, Metcalf D: Broad inter-individual variation in circulating progenitor cell numbers induced by granulocyte colony stimulating factor therapy. Stem Cells 1995; 13:512-516.
49. Sekhsaria S, Fleishcr TA, Vowells S, Brown M, Miller J, Gordon I, Blaese RM, Dunbar CE, Leitman S, Malech HL: Granulocyte colonystimulating factor recruitment of CD34+ progenitors to peripheral blood: Impaired mobilization in chronic granulomatous disease and adenosine deaminase-deficient severe combined immunodeficiency disease patients. Blood 1996;88:1104-1112.
50. Waller CF, Bertz H, Wenger MK, Fetscher S, Hardung M, Engelhardt M, Berhinger D, Lange W, Mertelsmann R, Finke J: Mobilization of peripheral blood progenitor cells for allogeneic transplantation: Efficacy and toxicity of a highdose rhG-CSF regimen. Bone Marrow Transplant 1996; 18:279-283.
51. Jones UM, Picozzi VJ, Price TH, Heimfeld MA, Eagan BL, Fogarty BL, Vanderbosch LJ, Benyunes MC, Krieger MS, Tamowski SJ: Peripheral blood progenitor harvest following mobilization using G-CSF: Experience in collections from 99 normal subjects (abstract 2705). Blood 1996;88:679a.
52. Geissler K, Peschel C, Niederwieser D, Strobl H, Goldschmitt J, Ohler L, Bettelheim P, Kahls P, Huber C, Lcchner K, Hocker P, Kolbe K: Potentiation of granulocyte colony-stimulating factor-induced mobilization of circulating progenitor cells by seven-day pretreatment with interleukin-3. Blood 1996;87:2732-2739.
53. Tricot G, Jagannath S, Desikan KR, Siegel D, Munshi N, Oison E, Wyres M, Parker W, Barlogie B: Superior mobilization of peripheral blood progenitor cells with r-metHuSCF (SCF) and r-methHuG-CSF (filgrastim) in heavily pretreated multiple myeloma patients (abstract 1540). Blood 1996;88:388a.
54. Basser R, Rasko J, Clarke K, Green M, Ccbon J, Grigg A, Berndt M, Zalcberg J, Marty J, Menchaca D, Tomita D, Fox R, Begley G: Pegylated megakaryocyte growth and development factor (PEG-rHuMGDF) enhances the mobilization of peripheral blood progenitor cells (PBPC) by chemotherapy and filgrastim (abstract 2558). Blood 1996;88:64 la.
55. Pruijt JFM, Figdor CG, van Kooyk Y, Willemze R, Fibbe WE: Anti-LFA-1 blocking antibodies prevent mobilisation of haematopoietic progenitor cells induced by interIeukin-8 (abstract 1886). Blood 1996;88:474a.
56. Lord BI, Woolford LB, Wood LM, Czaplewski LG, McCourt M, Hunter MG, Edwards RM: Mobilization of early hcmatopoietic progenitor cells with BB-I0010: A genetically engineered variant of human macrophage inflammatory protein-1 alpha. Blood 1995;85:3412-3415.
57. Watts MJ, Addison I, Sullivan AM, Chavda N, Jamieson E, Hunter M, Czaplewski L, Wood M, LinchDC:EffectsofasingledoseofBB-10010 on progenitor cell mobilization after cyclophosphamide and G-CSF (abstract 1049). Br J Haematol 1996;96:277a.
58. Sullivan AM, Watts MJ, Leverett D, Williams CD, Goldstone AH, Linch DC: Failure to mobilise peripheral blood stem cells reflects poor bone marrow quality (abstract 147). Br J Haematol 1996;93:39a.
59. Passos-Coelho JL, Braine HG, Davis JM, Huelskamp AM, Schepers KG, Ohly K, Clarke B, Wright SK, Noga SJ, Davidson NE: Predictive factors for peripheral blood progenitor cell collections using a single large volume leukapheresis after cyclophosphamide and granulocytemacrophage colony stimulating factor mobilization. J din Oncol 1995;13:705-714.
60. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Wilt B, Flentje M, Wannenmachcr M, Hunstein W: Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994;83:3787-3794.
61. Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, LilFeby K, Gooley T, Lynch M, Higano T, Klamet J: Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): An analysis of factors correlating with the tempo of engraftment after transplantation. Br J HaematolI994;87:825-831.
62. Koumakis G, Vassilomanolakis M, Hatzichristou H, Barbonis V, Fills J, Papanastasious K, Moraki M, Kritsioti M, Platanoitis G, Stamatelou M, Efremidis AP: Predictive factors affecting mobilization and peripheral blood stem cell (PBSC) collection using single apheresis (SA) for rescuing patients after high dose chemotherapy (HD.CHE) in various malignancies. Bone Marrow Transplant 1996; 18:1065-1072.
63. Anderlini P, Przepiorka D, Lauppe J, Huh YO, Seong D, Champlin R, Korbling M: Stem cell apheresis: Results of the M.D. Anderson protocol in 167 normal donors (abstract 2704). Blood 1996;88:679a.
64. Van Hoef MEHM: Guidelines for efficient peripheral blood progenitor cell collection (review). Neth J Med 1996;48:29-37.
65. Murea S, Goldschmidt H, Hahn U, Pforsich M, Moos M, Haas R: Successful collection and transplantation of peripheral blood stem cells in cancer patients using large-volume leukapheresis. J Clin Apheresis 1996; 11:185-194.
66. Watts MJ, Addison I, Linch DC: Comparison of progenitor cell mobilisation by glycosylated and non-glycosylated G-CSF given at a dose of 5 [ig/kg/day to normal volunteers (abstract 1570). Blood 1996;88:395a.
67. Linch DC, Milligan DW, Winfield DA, Kelsey S, Johnson S, Littlewood T, Smith G, Hutchinson MR, Goldstone AH, Fielding A, Williams M, Hartley S, Long SG: G-CSF significantly accelerates neutrophil recovery after peripheral blood stem cell transplantation (PBSCT) in lymphoma patients and shortens the time in hospital: Preliminary results of a BNLI randomised trial (abstract 873). Blood 1995;86:221 a.
68. Klumpp TR, Mangan KF, Goldberg ES, Pearlman ES, Macdonald JS: Granulocyte colonystimulating factor accelerates neutrophil engraftment following peripheral blood stem cell transplantation: A prospective, randomised trial. J Clin Oncol 1995;13:1323-1327.
69. Bensinger WI, Appelbaum F, Rowley S, Storb-R, Sanders J, Lilleby K, Gooley T, Demirer T, Schiffman K, Weaver C: Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995;13:2547-2555.
70. Shea TC, Mason JR, Stomiolo AM, Newton B, Breslin M, Müllen M, Ward DM, Miller L, Christian M, Taetle R: Sequential cycles of high dose carboplatin administered with recombinant human granulocyte macrophage colonystimulating factor and repeated infusions of autologous peripheral blood progenitor cells: A novel and effective method for delivering multiple courses of dose intensive therapy. J Clin Oncol 1992; 10:464-473.
71. Tepler I, Cannistra S, Gonin R, Anderson KC, Demetri G, Niloff J, Goodman H, Muntz H, Muto M: Use of peripheral blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol 1993;! 1: 1583-1591.
72. Brugger W, Birken R, Bertz H, Hecht T, Pressler K, Frisch J, Schulz G, Mertelsmann R, Kanz L: Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high dose VP16, ifosfamide andcispIatin.BrJHaematol I993;84:402-407.
73. Fielding AK, Goldstone AH, Sullivan AM, Watts MJ, Jamieson E, Linch DC: Peripheral blood stem cell support does not accelerate haemopoietic recovery from miniBEAM therapy. Bone Marrow Transplant 1996; 18:507-511.
74. Ossenkoppele GJ, Jonkhoff AR, Huijgens PC, Nauta JJ, van der Hem KG, Drager AM, Langenhuijsen MM: Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma. Bone Marrow Transplant 1994; 13:37-41.
75. Russell N: The place of blood stem cells in allogeneic transplantation (annotation). Br J Haematol 1996;93:747-753.
76. Cagnoni PJ, Shpall EJ: Mobilization and selection of CD34-positive hematopoietic progenitors. Blood Rev 1996;10:l-7.
77. Berenson RJ, Besinger WI, Hill RS, Andrews RG, Garcia Lopez J, Kalamasz DF, Still BJ, Spitzer G, Buckner CD, Bernstein ID: Engraftment after infusion of CD34+- marrow cells in patients with breast cancer or neuroblastoma. Blood 1991;77:1717-1722.
78. Maroleau JP, Brice P, Dal Cortivo L, Ferdinand JP, Robert I, Miclea JM, Chaibli P, Gisselbrecht C, Mills B, Kunkel L, Oldham F, Benbunan M: CD34+ selection by immunomagnetic selection (Isolex 300) for patients with malignancies (abstract 427). Blood 1996;88:110a.
79. Richel D, Johnsen H, Canon J, Schaafsma M, Schenkeveld C, Hansen S, McNiece I, Ewen C, Davies R, Miltenyi S, Guillaume T, Symann M: Highly purified CD34+ cells isolated with the Amgen cell selector provide rapid engraftment following high dose chemotherapy in breast cancer patients (abstract 429). Blood 1996;88: HOa.
80. Watts MJ, Sullivan AM, Goldstone AH, Linch DC: Feasibility of clinical scale CD34+ cell purification: Experience of 40 immunoaffinity column procedures (abstract 46). Br Haematol 1996;93:12a.
81. Watts MJ, Jones HM, Sullivan AM, Langabeer SE, Jamieson E, Fielding A, Williams C, Berenson RJ, Goldstone AH, Linch DC: Accessory cells do not contribute to G-CSF or IL-6 production nor to rapid haematological recovery following peripheral blood stem cell transplantation. Br J Hacmatol I995;91:767-772.
82. Brugger W, Henschler R, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L: Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high dose VPI6, ifosfamide, carboplatin, and epirubicin. Blood 1994;84:1421-1426.
83. Haylock DN, To LB, Dowse TI, Juttner CA, Simmons PJ: Ex-vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. Blood 1992;80:1405-1409.
84. Brugger W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L: Reconstitution of hematopoiesis after high dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl JMedl995;333:283-287.
85. Muench MO, Firpo MT, Moore MA: Bone marrow transplantation with interleukin-l plus kitligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential. Blood 1993;81:3463-3473.
86. Holyoake TL, Alcom MC, Richmond L, Pearson C, Farrell E, Kyle B, Dunlop DJ, Fitzsimmons E, Steward WP, Pragnell IB, Franklin IM: A phase I study to evaluate the safety of reinfusing CD34 cells expanded in vitro as part or all of a transplant procedure (abstract 1161). Blood 1995;86:294a.
87. Fisch P, Kohler G, Garbe A, Herbst B, Wider D, Kohler H, Schaefer HE, Mertelsmann R, Brugger W, Kanz L: Generation of antigen presenting cells for soluble protein antigens ex vivo from peripheral blood CD34+ hematopoietic progenitor cells in cancer patients. Eur J Immunol 1996;26:595-600.
88. Reid CDL: The dendritic cell lineage in haemopoiesis. Br J Haematol 1997;96:217-223.
89. Steinman RM: Dendritic cells and immunebased therapies. Exp Haematol 1997;24:859862.